The regulatory setback occurred when the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine, citing critical uncertainties in the company’s new drug application that required additional evidence. This decision effectively halted the progress of the bitopertin program, leaving investors to face significant losses following the immediate market reaction.

Rosen Law Firm, which specializes in securities litigation, is currently soliciting inquiries from shareholders who purchased Disc Medicine securities. The firm intends to seek compensation for affected investors through a contingency fee arrangement, meaning participants incur no out-of-pocket costs. Those interested in joining the prospective class action are encouraged to contact attorney Phillip Kim via the firm's website or by telephone to discuss potential recovery options.